OncoMatch/Clinical Trials/NCT06394492
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Is NCT06394492 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A1921 and Doxorubicin for ovarian cancer.
Treatment: SHR-A1921 · Doxorubicin · Paclitaxel · Topotecan — This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have platinum-resistant disease
Cannot have received: systemic anticancer treatments
Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment
Cannot have received: TOP1 inhibitor
Treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload
Cannot have received: antibody-drug conjugate
Treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload
Lab requirements
Blood counts
Adequate bone marrow reserve
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate bone marrow reserve and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify